Sprycel for chronic myeloid leukemia and Philadelphia chromosome - Positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 352-359

  Brave, Michael ^a   Goodman, Vicki ^a   Kaminskas, Edvardas ^a   Farrell, Ann ^a   Timmer, William ^a   Pope, Sarah ^a   Harapanhalli, Ravi ^a   Saber, Haleh ^a   Morse, David ^a   Bullock, Julie ^a   Men, Angela ^a   Noory, Carol ^a   Ramchandani, Roshni ^a   Kenna, Leslie ^a   Booth, Brian ^a   Gobburu, Joga ^a   Jiang, Xiaoping ^a   Sridhara, Rajeshwari ^a   Justice, Robert ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DASATINIB; FAMOTIDINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SIMVASTATIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BILIRUBIN BLOOD LEVEL; BLAST CELL; BLEEDING; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER PATIENT; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GENERALIZED EDEMA; HEADACHE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LABORATORY TEST; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; LUNG EDEMA; LUNG HEMORRHAGE; LYMPHOID CELL; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; MYCOSIS; NAUSEA; NEUTROPENIA; PAIN; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RASH; RESPIRATORY TRACT INFLAMMATION; SIDE EFFECT; SUBDURAL HEMATOMA; THORAX PAIN; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS PNEUMONIA; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38949134552     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4175     Document Type: Article

References (32)

1. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998;352:1087-92.
2. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441.
3. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-25.
4. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84:4064-77.
5. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomized, multicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-97.
6. Guilhot F, Chastang C, Michallet M, et al. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-29.
7. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukaemia. Blood 2002;99:1527-35.
8. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001;98:3074-81.
9. Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant α 2b interferonin patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-84.
10. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann Intern Med 1995;122:254-61.
11. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998;92:1541-8.
12. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-42.
13. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
14. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
15. Gleevec® prescribing information. Novartis Pharmaceutical Corporation, East Hanover, New Jersey 07936.
16. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
17. Shah NP. Loss of Response to Imatinib: Mechanisms and Management. American Society of Hematology Education Program Book; 2005;183-7.
18. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359:487-91.
19. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
20. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
21. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
22. Al-Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004;5:55-60.
23. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005;23:4100-09.
24. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85.
25. Widmer N, Colombo S, Buclin T, Decosterd LA, Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003;102:1142.
26. Gambacorti-Passerini C, Barni R, Le CP, et al. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641-50.
27. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chromic phase CML patients treated with imatinib mesylate. Blood 2004;103:451.
28. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-97.
29. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-75.
30. Code of Federal Regulations, Part 314.126. Adequate and Well Controlled Studies. Apr. 7, 2007 edition.
31. Code of Federal Regulations, Part 314.530, Subpart H-Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Apr. 7, 2007 edition.
32. Fridericia LS. Die Systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 1920;53:489.